Welcome to our dedicated page for Ludwig Enter news (Ticker: LUDG), a resource for investors and traders seeking the latest updates and insights on Ludwig Enter stock.
Ludwig Enterprises, Inc. (LUDG) delivers cutting-edge solutions at the intersection of mRNA genomics and artificial intelligence. This news hub provides investors and healthcare professionals with essential updates on the company's non-invasive diagnostic innovations, strategic partnerships, and clinical research developments.
Access real-time updates on FDA submissions, intellectual property milestones, and Revealia™ cancer screening enhancements. Our curated news collection covers earnings announcements, preclinical study results, and AI algorithm advancements that power the company's proprietary inflammatory index.
Key focus areas include mRNA biomarker discoveries, machine learning model refinements, and collaborations with leading medical institutions. Track progress in early detection technologies for chronic inflammation-related diseases, including breast cancer and cardiovascular conditions.
Bookmark this page for streamlined access to Ludwig's regulatory filings, executive commentary, and peer-reviewed research findings. Subscribe to our alerts for immediate notifications about material developments in this dynamic biotechnology sector.
Ludwig Enterprises has initiated discussions with Emerson Urology Associates to conduct a clinical study on bladder cancer patients' response to BCG immunotherapy. This collaboration aims to utilize Ludwig's proprietary genetic inflammatory biomarkers to create a predictive model for early-stage cancer diagnosis and treatment response. Ludwig's biomarker panel is currently being submitted for U.S. patent approval. With bladder cancer accounting for approximately 83,000 new cases annually in the U.S., this study could significantly impact treatment methodologies.
Ludwig (OTC PINK:LUDG) has announced a new business plan aimed at tackling chronic inflammation, a significant healthcare crisis linked to various diseases. The company acquired proprietary research data and an mRNA patient genetic database for developing a unique Ludwig mRNA Inflammatory Index™. Key milestones include hiring Dr. Marvin S. Hausman as Chief Science Consultant and forming an AI division for biological data analysis. Ludwig raised $200,000 without diluting capital and is preparing for an S1 filing to potentially uplist to NASDAQ, signaling growth prospects for shareholders.
Ludwig Enterprises, Inc. (OTC PINK:LUDG) announced significant changes aimed at its potential IPO ambitions. The appointment of Anne Blackstone as the new CEO, along with the addition of Data Science Expert Kyle Ambert, Ph.D. and renowned physician Dr. Marvin S. Hausman, enhances the company's leadership team. The firm has also engaged a public accounting firm as an independent auditor and retained Newlan Law Firm for legal support. These developments reflect Ludwig's commitment to operational transparency and becoming an SEC-reporting entity.
Ludwig (OTC PINK:LUDG) announced the appointment of Dr. Kyle H. Ambert, PhD, to its Scientific Advisory Board (SAB) effective immediately. Dr. Ambert, the current Director of Data Science at Nike, brings expertise in data analytics, machine learning, and biomedical informatics. He will act as a consultant for Ludwig and its subsidiary, mRNA for Life, Inc., aiding in the design and analysis of clinical studies. Dr. Marvin S. Hausman, Chairman of the SAB, expressed confidence in Dr. Ambert’s role in advancing cancer diagnosis and treatment through proprietary genetic biomarkers.
Ludwig Enterprises (OTC PINK:LUDG) has announced the appointment of Dr. Marvin Hausman as its Chief Science Consultant, aiming to enhance the company's credibility in medical technology. Dr. Hausman, an experienced immunologist and urological surgeon, boasts over 40 years in drug research and development across prominent pharmaceutical companies. His strong background is expected to guide Ludwig in its direction towards breakthrough medical technologies. This move is part of Ludwig's strategic shift to focus on health-related innovations.
Ludwig Enterprises Inc. (LUDG) has appointed Anne Blackstone, CRNA, as its new CEO, signaling a strategic shift back to health technology. Blackstone, who previously led mRNAforLife, Inc., is focused on acquisitions that enhance the company's health sector presence. She emphasizes innovative products and upcoming announcements that could significantly impact healthcare, particularly in mRNA technology. This leadership change comes amidst recent funding successes, aligning with Ludwig's mission to prioritize health-related advancements.
Ludwig Enterprises Inc. (OTC PINK:LUDG) announced that its note holders have waived interest on long-term debt, enhancing the company's financial position. This strategic shift back to its core technology and health-related projects includes securing $200,000 in private equity funding. The company anticipates further funding as it prepares for potential uplisting, joint ventures, or acquisitions. The Board believes these changes serve the best interests of shareholders as they navigate these evolving business opportunities.
Ludwig Enterprises Inc. (OTC PINK:LUDG) announced the successful completion of its first round of new project funding, receiving $200,000 in private equity. The company has divested from its financial services unit to focus on technology and health-related projects. On May 18, 2022, Anne Blackstone was appointed CEO and sole director of mRNAforLife, Inc., a subsidiary aimed at health field acquisitions. Following Jean Cherubin's retirement on June 1, 2022, Blackstone also became CEO and Director of Ludwig Enterprises, indicating a strategic shift back to core business interests.
Ludwig Enterprises (OTC PINK:LUDG) announced a resolution to call $80,471.67 of convertible notes, leading to the issuance of 8,047,167 new common shares at $0.01 per share. The company is in the process of unwinding its relationship with Direct Mortgage Investors, resulting in an asset loss exceeding $600,000. Ludwig aims to focus on its core operations in technology and health-related fields. Additionally, it is monitoring third-party litigation related to ownership of 28 million shares.
Ludwig Enterprises Inc. has decided to unwind its subsidiary Direct Mortgage Investors, Inc., effective immediately. This move aims to refocus on technology and health-related sectors after Direct operated as a wholly owned subsidiary since 2019. Although Ludwig anticipates a short-term asset loss exceeding $600,000, the Board believes this strategic decision will enhance long-term shareholder value. Additionally, a third-party litigation regarding approximately 28 million Ludwig shares is being monitored, although neither party is involved in the case.
